1
However, the effects of myocardial ECM alterations on systolic function remain to be determined.
2
The primary outcome measure is change in myocardial ECM volume.
3
Conclusion and clinical relevance: In conclusion, quantification and characterization of human myocardial ECM showed significant patient-to-patient variability between the six investigated patients.
4
This is an important outcome for the development of allogeneic derived biomaterials and for increasing our understanding of human myocardial ECM composition.
5
Galectin-3 (Gal-3) is a mediator of myocardial ECM metabolism and biomarker for left heart remodeling, yet its ability to reflect RV remodeling is unknown.